clinical trial · NCT07082803
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Treeline Biosciences, Inc.·phase1·recruiting·n = 180
LymphomaLymphoma, Non HodgkinTLN-121TLN-254TLN-121
brief summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
started
Jun 23, 2025
primary completion
Sep 1, 2030
completion
Nov 1, 2030
last updated
Mar 27, 2026
official title
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol